Aaron Hardin

Aaron Hardin

Auto-generated profile, based on publicly available information

Aaron Hardin

Guardant Health, Palo Alto, CA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2019 in Science
Verified
Journal Article
Closed access
PDF file
NMNavneet Matharu
Navneet Matharu
SRSawitree Rattanasopha
Sawitree Rattanasopha
STSerena Tamura
Serena Tamura
LMLenka Maliskova
Lenka Maliskova
YWYi Wang
Yi Wang
NANadav Ahituv
Nadav Ahituv
CRISPRa corrects haploinsufficient obesity: Loss-of-function mutation in one gene copy, termed haploinsufficiency, can lead to insufficient protein levels and result in human disease. Matharu et al. tested whether a CRISPR-based activation system (CRISPRa) could rescue a haploinsufficient phenotype by increasing the gene expression levels of the existing normal copy (see the Perspective by Montefiori and Nobrega). By delivering this system into the mouse hypothalamus using adeno-associated virus, they rescued the obesity phenotype caused by haploinsufficiency of either of two genes known to promote obesity when mutated in mice and humans. These results highlight the translational potential of the CRISPR activation system to treat haploinsufficient disease. Science , this issue p. eaau0629 ; see also p. 231

2 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
CCChhayheng Chhoeu
Chhayheng Chhoeu
JLJiaqi Li
Jiaqi Li
KPKristin S. Price
Kristin S. Price
LKLesli A. Kiedrowski
Lesli A. Kiedrowski
PJPasi Antero Jänne
Pasi Antero Jänne

1 June 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NVNeelima Vidula
Neelima Vidula
TRThereasa A. Rich
Thereasa A. Rich
OSOliver Sartor
Oliver Sartor
JYJennifer Yen
Jennifer Yen
AHAaron Hardin
Aaron Hardin
MCMassimo Cristofanilli
Massimo Cristofanilli
Purpose: Poly ADP-ribose inhibitors (PARPi) are efficacious in multiple cancers harboring germline (and possibly somatic) BRCA1/2 mutations. Acquired reversions can restore BRCA1/2 function, causing resistance to PARPi and/or platinum-based chemotherapy. The optimal method of identifying patients with germline, somatic, and/or reversion mutations in BRCA1/2 has not been established. Next-generation sequencing (NGS) of cell-free DNA (cfDNA) provides a platform to identify these three types of BRCA1/2 mutations. Methods: Patients with advanced breast, ovarian, prostate, or pancreatic cancer were tested using a clinically validated 73-gene cfDNA assay which evaluates single nucleotide variants and insertion-deletion mutations (indels) in BRCA1/2, and distinguishes somatic/reversion from germline mutations with high accuracy. Results: Among 828 patients, greater than or equal to 1 deleterious BRCA1/2 mutation was detected in 60 (7.2%) patients, including germline (n=42) and somatic (n=18) mutations. Common co-existing mutations included TP53 (61.6%), MYC (30%), PIK3CA (26.6%), BRAF (15%) and ESR1 (11.5%). Polyclonal reversion mutations (median, 5) were detected in 9/42 (21.4%) germline BRCA1/2 mutant patients, the majority (77.7%) of whom had prior PARPi exposure (median duration, 10 months). Serial cfDNA demonstrated emergence of reversion BRCA mutations under therapeutic pressure from initial PARPi exposure which contributed to subsequent resistance to PARPi and platinum therapy. Conclusions: cfDNA NGS identified high rates of therapeutically relevant mutations without foreknowledge of germline or tissue-based testing, including deleterious somatic BRCA1/2 mutations missed by germline testing and reversion mutations that can have important treatment implications. Further research is needed to confirm clinical application of these findings to guide precision medicine approaches for advanced malignancies.

1 September 2023 in JCO Precision Oncology
Verified
Journal Article
Closed access
Pashtoon Murtaza KasiPashtoon Murtaza Kasi
Pashtoon Murtaza Kasi
LBLeslie A. Bucheit
Leslie A. Bucheit
JLJiemin Liao
Jiemin Liao
JSJason Starr
Jason Starr
PBPedro Barata
Pedro Barata
JOJustin I. Odegaard
Justin I. Odegaard
MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.

20 May 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FSFrank Sinicrope
Frank Sinicrope
DSDiana Segovia
Diana Segovia
NSNalin Sharma
Nalin Sharma
SASteven Alberts
Steven Alberts
AHAaron Hardin
Aaron Hardin
QSQian Shi
Qian Shi
PURPOSE: Detection of molecular residual disease using circulating tumor DNA (ctDNA) may enable postoperative risk stratification and guide adjuvant therapy. We evaluated the prognostic value of a tissue-free, epigenomic ctDNA assay in patients with stage III colon cancer (CC) enrolled in a phase III adjuvant chemotherapy trial. METHODS: Plasma samples were collected after surgery and before adjuvant infusional fluorouracil, leucovorin, and oxaliplatin alone or combined with cetuximab. ctDNA was analyzed using a tissue-free assay; in ctDNA-positive patients, tumor fraction (TF) was quantified and genotyping was performed with a 739-gene panel. Associations with disease-free survival (DFS), time to recurrence (TTR), and overall survival (OS) were assessed using multivariable Cox models adjusted for covariates. RESULTS: Among 2,260 evaluable patients, 461 (20.4%) were ctDNA-positive with significantly higher detection in advanced T-/N-stage, high-grade, obstruction/perforation, and BRAF V600E tumors. At a median follow-up of 6.1 years, ctDNA positivity was independently associated with shorter TTR (hazard ratio [HR], 5.96 [95% CI, 5.11 to 6.96]), DFS (HR, 5.03 [95% CI, 4.36 to 5.81]), and OS (HR, 4.45 [95% CI, 3.76 to 5.27]; all P < .0001). The 5-year DFS was 27.7% (95% CI, 23.8 to 32.2) v 77.1% (95% CI, 75.1 to 79.1) in ctDNA-positive versus ctDNA-negative patients, and adverse prognostic impact was greater in lower T/N stage, low-risk, and dMMR subsets (interaction P = .0012-.041). Among ctDNA-positive patients, TF was nearly double in those who recurred or died ( P = .0002) and stratified patients for TTR, DFS, and OS (all adjusted P < .002). Genotyping identified mutations in FLT1 (OR, 8.99) and PREX2 (OR, 7.73) genes that were most strongly associated with recurrence ( P < .03). CONCLUSION: Evaluation of ctDNA in resected stage III CC using a tissue-free assay provided robust and independent prognostic value. Higher ctDNA burden, dMMR, and specific mutations defined poor prognostic groups among ctDNA-positive patients.

20 August 2019 in Molecular Biology and Evolution
Verified
Journal Article
Open access
PDF file
AHAaron Hardin
Aaron Hardin
KNKimberly A Nevonen
Kimberly A Nevonen
WEWalter L Eckalbar
Walter L Eckalbar
LCLucia Carbone
Lucia Carbone
NANadav Ahituv
Nadav Ahituv
Mastomys are the most widespread African rodent and carriers of various diseases such as the plague or Lassa virus. In addition, mastomys have rapidly gained a large number of mammary glands. Here, we generated a genome, variome, and transcriptomes for Mastomys coucha. As mastomys diverged at similar times from mouse and rat, we demonstrate their utility as a comparative genomic tool for these commonly used animal models. Furthermore, we identified over 500 mastomys accelerated regions, often residing near important mammary developmental genes or within their exons leading to protein sequence changes. Functional characterization of a noncoding mastomys accelerated region, located in the HoxD locus, showed enhancer activity in mouse developing mammary glands. Combined, our results provide genomic resources for mastomys and highlight their potential both as a comparative genomic tool and for the identification of mammary gland number determining factors.